Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa

Clinical Infectious Diseases

Volumn 40, Issue SUPPL., 2005, Pages

  Lister, Philip D ^a   Walter, Daniel J ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM; LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EVALUATION; GENE; GENE MUTATION; GENE OVEREXPRESSION; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LOG PHASE CULTURE; MEXEF OPRN GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRAIN IDENTIFICATION; TRANSCRIPTION REGULATION;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 13944272614     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/426190     Document Type: Article

References (29)

1. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Arch Intern Med 1996; 156:2121-6.
2. Sanders CC, Sanders WE Jr. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15:824-39.
3. Kohler T, Michea-Hamzehpour M, Epp SF, et al. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43:424-7.
4. Masuda N, Sakagawa E, Ohya S, et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44:3322-7.
5. Gotoh N, Tsujimoto H, Tsuda M, et al. Characteriziation of the MexC-MexD-OprJ multidrug efflux system in mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42:1938-43.
6. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39:645-9.
7. Yoneyama H, Nakae T. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37:2385-90.
8. Pirnay J-P, Vos DD, Mossialos D, et al. Analysis of the Pseudomonas aeruginosa oprD gene from clinical isolates and environmental isolates. Environ Microbiol 2002; 4:872-82.
9. Kohler T, Michea-Hamzehpour M, Henze U, et al. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997; 23:345-54.
10. Masuda N, Ohya S. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36:1847-51.
11. Fukuda H, Hosaka M, Iyobe S, et al. nfxC-type quinolone resistance in clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39:790-2.
12. NCCLS. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement (M100-S9). Wayne, PA: NCCLS, 1999.
13. Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 1985; 15:131-7.
14. Lister PD, Sanders WE Jr, Sanders CC. Cefepime-aztreonam: a unique double β-lactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42:1610-9.
15. Chien S-C, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42:885-8.
16. Physicians desk reference: medical economics data. 54th edition. Mazum JM, Woerner RN, eds. Montvale, NJ: Medical Economics Company, 2001.
17. Edberg SC. The measurement of antibiotics in human fluids: techniques and significance. In: Lorian V, ed. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins, 1986:381-476.
18. Zabinski RA, Larsson AJ, Walker KJ, et al. Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads. Antimicrob Agents Chemother 1993; 37:1377-9.
19. Sanders CC, Sanders WE. Emergence of resistance during therapy with the newer β-lactam antibiotics: role of inducible β-lactamases and implications for the future. Rev Infect Dis 1983; 5:639-18.
20. Masterton RG, Garner PJ, Harrison NA, et al. Timentin resistance. Lancet 1987; 2:975-6.
21. Letendre ED, Mantha R, Turgeon PL. Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis. J Antimicrob Chemother 1988; 22:557-62.
22. Scully BE, Ores CN, Prince AS, et al. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Rev Infect Dis 1985; 7(Suppl 4):S669-74.
23. Sanders WE, Sanders CC. Inducible β-lactamases: clinical and epidemiological implications for use of newer cephalosporins. Rev Infect Dis 1988; 10:830-8.
24. Giwercman B, Lambert PA, Rosdahl VT, Shand GH, Hoiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially-derepressed β-lactamase-producing strains. J Antimicrob Chemother 1990; 26:247-59.
25. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406:959-64.
26. Mathai D, Lewis MT, Kugler KC, et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I - results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 2001; 39:105-16.
27. Jones RN, Beach ML, Pfaller MA. Spectrum of activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosaisolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagn Microbiol Infect Dis 2001; 41:161-3.
28. Kirby JT, Mutnic AH, Jones RN, et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002; 43:303-9.
29. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 2002; 62:13-59.